1. Home
  2. SUPN vs VVX Comparison

SUPN vs VVX Comparison

Compare SUPN & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • VVX
  • Stock Information
  • Founded
  • SUPN 2005
  • VVX 2014
  • Country
  • SUPN United States
  • VVX United States
  • Employees
  • SUPN N/A
  • VVX N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • VVX Diversified Commercial Services
  • Sector
  • SUPN Health Care
  • VVX Consumer Discretionary
  • Exchange
  • SUPN Nasdaq
  • VVX Nasdaq
  • Market Cap
  • SUPN 1.8B
  • VVX 1.6B
  • IPO Year
  • SUPN 2012
  • VVX 2014
  • Fundamental
  • Price
  • SUPN $33.96
  • VVX $48.88
  • Analyst Decision
  • SUPN Hold
  • VVX Buy
  • Analyst Count
  • SUPN 2
  • VVX 9
  • Target Price
  • SUPN $36.00
  • VVX $64.11
  • AVG Volume (30 Days)
  • SUPN 760.7K
  • VVX 249.9K
  • Earning Date
  • SUPN 08-05-2025
  • VVX 08-04-2025
  • Dividend Yield
  • SUPN N/A
  • VVX N/A
  • EPS Growth
  • SUPN N/A
  • VVX N/A
  • EPS
  • SUPN 1.11
  • VVX 1.29
  • Revenue
  • SUPN $667,997,000.00
  • VVX $4,327,514,000.00
  • Revenue This Year
  • SUPN N/A
  • VVX $4.02
  • Revenue Next Year
  • SUPN $12.02
  • VVX $4.80
  • P/E Ratio
  • SUPN $29.92
  • VVX $37.98
  • Revenue Growth
  • SUPN 11.82
  • VVX 7.38
  • 52 Week Low
  • SUPN $27.05
  • VVX $41.08
  • 52 Week High
  • SUPN $40.28
  • VVX $69.75
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 66.18
  • VVX 57.57
  • Support Level
  • SUPN $32.49
  • VVX $48.84
  • Resistance Level
  • SUPN $33.80
  • VVX $50.29
  • Average True Range (ATR)
  • SUPN 0.91
  • VVX 1.25
  • MACD
  • SUPN 0.23
  • VVX 0.15
  • Stochastic Oscillator
  • SUPN 99.37
  • VVX 69.69

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

Share on Social Networks: